Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) FCF Margin (2019 - 2025)

Historic FCF Margin for Revolution Medicines (RVMD) over the last 6 years, with Q3 2025 value amounting to 1843.37%.

  • Revolution Medicines' FCF Margin changed N/A to 1843.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 6799.79%, marking a year-over-year increase of 810736400.0%. This contributed to the annual value of 3094.14% for FY2023, which is 24293100.0% down from last year.
  • Per Revolution Medicines' latest filing, its FCF Margin stood at 1843.37% for Q3 2025.
  • Revolution Medicines' FCF Margin's 5-year high stood at 1843.37% during Q3 2025, with a 5-year trough of 16560.65% in Q4 2023.
  • Over the past 4 years, Revolution Medicines' median FCF Margin value was 695.86% (recorded in 2022), while the average stood at 2123.2%.
  • As far as peak fluctuations go, Revolution Medicines' FCF Margin soared by 17177300bps in 2022, and later plummeted by -161388300bps in 2023.
  • Revolution Medicines' FCF Margin (Quarter) stood at 427.57% in 2021, then rose by 1bps to 421.81% in 2022, then plummeted by -3826bps to 16560.65% in 2023, then surged by 111bps to 1843.37% in 2025.
  • Its FCF Margin was 1843.37% in Q3 2025, compared to 16560.65% in Q4 2023 and 1784.52% in Q2 2023.